Literature DB >> 3890149

IgE-containing circulating immune complexes in Churg-Strauss vasculitis.

B J Manger, F E Krapf, M Gramatzki, H G Nüsslein, G R Burmester, P B Krauledat, J R Kalden.   

Abstract

In five patients with vasculitis, hypereosinophilia, and elevated serum IgE levels a diagnosis of Churg-Strauss syndrome was established. To identify a possible role of IgE in pathogenic mechanisms leading to the vasculitis, we performed a sequential precipitation of the patients' sera with different concentrations of polyethylene glycol (PEG) 6000. Using a radio immunosorbent test, we tested the precipitates obtained for IgE. Considerable amounts of IgE were traced in the serum precipitates of all patients, especially after the second precipitation step (4.0% PEG). In contrast, no IgE-containing precipitates were detectable in sera from patients with different allergic diseases and high IgE serum levels. Together with an increase in C3d serum levels and the failure to demonstrate C1q-binding material in patients' sera, these data suggest the involvement of IgE-containing immune complexes in the pathogenesis of Churg-Strauss vasculitis, activating the complement via the alternate pathway.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3890149     DOI: 10.1111/j.1365-3083.1985.tb01443.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  16 in total

Review 1.  Innate immune cells in the pathogenesis of primary systemic vasculitis.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2015-09-24       Impact factor: 2.631

Review 2.  Clinical significance of anti-IgE autoantibodies and immune complexes containing IgE.

Authors:  C G Magnusson; S G Johansson
Journal:  Clin Rev Allergy       Date:  1989

3.  Antibody binding of macromolecular DNA and RNA in the plasma of SLE patients.

Authors:  F Krapf; M Herrmann; W Leitmann; J R Kalden
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

4.  Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis.

Authors:  Peter C Grayson; Paul A Monach; Christian Pagnoux; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen Maksimowicz-McKinnon; Philip Seo; Ulrich Specks; Steven R Ytterberg; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2014-11-17       Impact factor: 7.580

Review 5.  Treatment of vasculitis.

Authors:  H G Taylor; A Samanta
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

6.  Relationship of serum alpha-fetoprotein to circulating immune complexes and complements in patients with hepatitis B surface antigen-positive hepatocellular carcinoma.

Authors:  J F Tsai; J H Tsai; W Y Chang
Journal:  Gastroenterol Jpn       Date:  1990-06

7.  [Immune complexes in allergies: evidence of IgE-containing immune complexes in Churg-Strauss vasculitis].

Authors:  F E Krapf; B K Manger; J R Kalden
Journal:  Klin Wochenschr       Date:  1986-06-16

8.  Establishment of experimental eosinophilic vasculitis by IgE-mediated cutaneous reverse passive arthus reaction.

Authors:  Takayuki Ishii; Tomoyuki Fujita; Takashi Matsushita; Koichi Yanaba; Minoru Hasegawa; Hiroko Nakashima; Fumihide Ogawa; Kazuhiro Shimizu; Kazuhiko Takehara; Thomas F Tedder; Shinichi Sato; Manabu Fujimoto
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

Review 9.  [Hypereosinophilic syndrome and Churg-Strauss syndrome: is it clinically relevant to differentiate these syndromes?].

Authors:  B Hellmich; K Holl-Ulrich; H Merz; W L Gross
Journal:  Internist (Berl)       Date:  2008-03       Impact factor: 0.743

10.  IGM-containing immune complexes and antiphospholipid antibodies in patients with Sneddon's syndrome.

Authors:  E Schulze-Lohoff; F Krapf; L Bleil; G R Burmester; K Kölble; H G Nüsslein; W Rödl; J R Kalden
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.